非肌层浸润性膀胱癌的最佳卡介苗剂量是多少？ - Suppr

Suppr

超能文献

What is the optimal BCG dose in non-muscle-invasive bladder cancer?

作者信息

Witjes J Alfred

出版信息

Eur Urol. 2007 Nov;52(5):1300-2. doi: 10.1016/j.eururo.2007.05.010. Epub 2007 May 22.

DOI:10.1016/j.eururo.2007.05.010

PMID:17531374

Abstract

摘要

相似文献

What is the optimal BCG dose in non-muscle-invasive bladder cancer?

Eur Urol. 2007 Nov;52(5):1300-2. doi: 10.1016/j.eururo.2007.05.010. Epub 2007 May 22.

Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

Eur Urol. 2008 May;53(5):1002. doi: 10.1016/j.eururo.2007.10.007. Epub 2007 Oct 15.

Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?

Eur Urol. 2007 Oct;52(4):951-3; discussion 953-4. doi: 10.1016/j.eururo.2007.03.028. Epub 2007 Mar 15.

Management of BCG "Failures".

Eur Urol. 2006 May;49(5):779-80. doi: 10.1016/j.eururo.2006.03.006. Epub 2006 Mar 20.

[BCG therapy. Its role in the treatment of tumors of the bladder].

Ann Urol (Paris). 1995;29(5):292-3.

Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.

Eur Urol. 2010 Aug;58(2):e23; author reply e24-5. doi: 10.1016/j.eururo.2010.05.032. Epub 2010 Jun 2.

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

Urology. 2008 Feb;71(2):297-301. doi: 10.1016/j.urology.2007.09.050.

[The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].

Hinyokika Kiyo. 2005 Aug;51(8):529-31.

[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].

Prog Urol. 2012 Nov;22(15):920-31. doi: 10.1016/j.purol.2012.05.002. Epub 2012 Jun 15.

A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.

BJU Int. 2009 Jul;104(2):184-8. doi: 10.1111/j.1464-410X.2008.08342.x. Epub 2009 Jan 19.

引用本文的文献

The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology.

J Urol. 2016 Jun;195(6):1903-10. doi: 10.1016/j.juro.2015.11.073. Epub 2015 Dec 13.

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Open Access J Urol. 2010 May 19;2:67-84.

Assessment of angiogenic factor, vascular endothelial growth factor, serum and urine level changes in superficial bladder tumor immunotherapy by intravesical Bacillus Calmette-Guerin.

Urol Ann. 2010 Sep;2(3):91-5. doi: 10.4103/0974-7796.68855.

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Immunotherapy. 2009 Mar;1(2):281-8. doi: 10.2217/1750743X.1.2.281.

[Intravesical therapy in non-muscle-invasive bladder cancer: indications and practical considerations].

Urologe A. 2009 Nov;48(11):1263-4, 1266-8, 1270-2. doi: 10.1007/s00120-009-2105-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验